<DOC>
	<DOCNO>NCT00099580</DOCNO>
	<brief_summary>This Phase 2 , randomize , placebo-controlled , multicenter outpatient study design test safety tolerability AC2592 well examine effect AC2592 oxygen consumption maximal tolerate exercise adult subject chronic congestive heart failure .</brief_summary>
	<brief_title>PROCLAIM : Effect AC2592 Administered Continuous Subcutaneous Infusion Subjects With Advanced Chronic Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Main Has heart failure classify New York Heart Association ( NYHA ) Class III Class IV screen despite treatment standard therapy . Is able perform treadmill test . Has HbA1c &lt; = 11 % . Is physically mentally capable operate continuous subcutaneous infusion ( CSCI ) pump ( i.e. , adequate vision , manual dexterity , mental capacity ) , dedicate caretaker adult family member meet requirement . Main Has receive metformin nesiritide within 2 week prior screen visit . Is currently participate clinical study , receive investigational drug within 1 month screen period . Has participate previously study use GLP1 , exenatide , exenatide LAR . Is use left ventricular assist device mechanical circulatory support .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>AC2592</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Amylin</keyword>
	<keyword>metabolic abnormality</keyword>
</DOC>